Randomized trials of ombitasvir/paritaprevir/r+dasabuvir±ribavirin vs telaprevir+pegIFN/ribavirin in adults with genotype 1 HCV

Telaprevir plus peginterferon/ribavirin(TPV+pegIFN/RBV) remains a therapeutic option for chronic HCV genotype(GT) 1 infection in many regions. We conducted two open-label, phase 3b trials comparing safety and efficacy of all-oral ombitasvir/paritaprevir/ritonavir and dasabuvir+/-ribavirin(OBV/PTV/r+DSV+/-RBV) and TPV+pegIFN/RBV.

Source: Journal of Hepatology - August 27, 2015 Category: Gastroenterology Authors: Gregory J. Dore, Brian Conway, Yan Luo, Ewa Janczewska, Brygida Knysz, Yan Liu, Adrian Streinu-Cercel, Florin Alexandru Caruntu, Manuela Curescu, Richard Skoien, Wayne Ghesquiere, Włodzimierz Mazur, Alejandro Soza, Francisco Fuster, Susan Greenbloom, Adr Source Type: research